The Indian Journal of Chest Diseases and Allied Sciences

Register      Login

VOLUME 62 , ISSUE 4 ( October-December, 2020 ) > List of Articles


National TB Elimination Programme––Can It End TB in India by 2025: An Appraisal

D. Behera, Viraaj Pratap Singh Pannu, Ranjan Kumar Behera

Keywords : End-TB strategy, NTEP, RNTCP, NSP, NIKSHAY, Latent TB infection, Diabetes, Chemoprophylaxis, COVID, Epidemiology, Nutrition, Health-care workers

Citation Information : Behera D, Pannu VP, Behera RK. National TB Elimination Programme––Can It End TB in India by 2025: An Appraisal. Indian J Chest Dis Allied Sci 2020; 62 (4):203-227.

DOI: 10.5005/ijcdas-62-4-203

License: CC BY-NC 4.0

Published Online: 07-11-2022

Copyright Statement:  Copyright © 2020; The Author(s).


India has the ambitious plan to End TB by 2025 which is five years ahead of the global strategy. To emphasise the point and not to be complaisant, the earlier Revised National Tuberculosis Control Programme (RNTCP) has been renamed as the National Tuberculosis Elimination Programme (NTEP) since January 2020. In this comprehensive review, various issues, weaknesses, strategies and their associated problems have been discussed. Starting with the problems of tuberculosis (TB) magnitude particularly latent TB infection, co-morbid conditions, like human immunodeficiency virus (HIV), diabetes mellitus, smoking, over-crowding, under-nutrition, immune-suppression, occupations like silicosis, etc have been reviewed and highlighted. Case notification, participation of private sector, diagnostic and treatment issues are discussed. Drug resistant TB (DR-TB) has also been described. Newer advances like molecular testing and treatment modalities including short course treatment and standardised longer regimens with injection free protocols are followed by the programme so that it will be possible in future for the patients to be diagnosed early, become more compliant and the treatment success will improve. Issues regarding prevention of TB in India with chemoprophylaxis, airborne infection control and future of vaccines are discussed in brief. National Strategic Plan (NSP) for 2017-25 and the Draft NSP for 2020- 25 are also discussed with their possible impact to End TB by 2025.

PDF Share
  1. Nikshay dash board. Central Tuberculosis Division, Ministry of Health and Family Welfare Government of India Available at URL: nikshay. Accessed on July 20, 2020.
  2. Behera D. TB control: role of DOTS. Expert Rev Respir Med 2009;3:557–60.
  3. Behera D. Issues in the management of drug resistant tuberculosis in India. Lung India 2013;30:269–72.
  4. Behera D. New strategies of TB control in India: are we on the right track? Indian J Tuberc 2012;59:130–4.
  5. Behera D. Tuberculosis control in India--a view point. Indian J Tuberc 2007;54:63–65.
  6. Prasad R, Gupta N, Banka A. 2025 too short time to eliminate tuberculosis from India. Lung India 2017;34:409–10.
  7. World Health Organization. Implementing the end TB strategy: the essentials: The end TB Strategy. Geneva: World Health Organization 2015. Available at URL: Accessed on July 20, 2020.
  8. Revised National Tuberculosis Control Programme. National strategic plan for tuberculosis elimination 2017–
  9. Ministry of Health and Family Welfare Government of India 2017. Available at URL: nikshay. Accessed on July 20, 2020.
  10. National Tuberculosis Elimination Program. National strategic plan to end tuberculosis in India 2020–2025. Ministry of Health and Family Welfare Government of India 2020. Available at URL: nikshay. Accessed on July 20, 2020.
  11. Chadha VK, Kumar P, Anjinappa SM, Singh S, Narasimhaiah S, Joshi MV, et al. Prevalence of pulmonary tuberculosis among adults in a rural sub-district of South India. PLoS One 2012;7:e42625.
  12. Chadha VK, Anjinappa SM, Dave P, Rade K, Baskaran D, Narang P, et al. Sub-national TB prevalence surveys in India, 2006-2012: results of uniformly conducted data analysis. PLoS One 2019;14:e0212264.
  13. Aggarwal AN, Gupta D, Agarwal R, Sethi S, Thakur JS, Anjinappa SM, et al. Prevalence of pulmonary tuberculosis among adults in a north Indian district. PLoS One 2015;10:e0117363.
  14. Narang P, Mendiratta DK, Tyagi NK, Jajoo UN, Tayade AT, Parihar PH, et al. Prevalence of pulmonary tuberculosis in Wardha district of Maharashtra, Central India. J Epidemiol Global Health 2015;5(Suppl. 1):S11–8.
  15. Sathiyamoorthy R, Kalaivani M, Aggarwal P, Gupta SK. Prevalence of pulmonary tuberculosis in India: a systematic review and meta-analysis. Lung India 2020;37:45–52.
  16. Houben RM, Dodd PJ. The global burden of latent tuberculosis infection: a re-estimation using mathematical modeling. PLoS Med 2016;13:e1002152.
  17. Matteelli A, Sulis G, Capone S, D'Ambrosio L, Migliori GB, Getahun H. Tuberculosis elimination and the challenge of latent tuberculosis. Presse Med 2017;46(2 Pt 2):e13–e21.
  18. Sharma SK, Mohanan S, Sharma A. Relevance of latent TB infection in areas of high TB prevalence. Chest 2012;142:761–73.
  19. Chee CBE, Reves R, Zhang Y, Belknap R. Latent tuberculosis infection: opportunities and challenges. Respirology 2018;23:893–900.
  20. Kashyap RS, Nayak AR, Gaherwar HM, Husain AA, Shekhawat SD, Jain RK, et al. Latent TB infection diagnosis in population exposed to TB subjects in close and poor ventilated high TB endemic zone in India. PLoS One 2014;9: e89524.
  21. Malaviya AN, Thakaran R, Rawat R, Kapoor S, Garg S, Baghel SS, et al. Real life experience of a screening strategy for latent tuberculosis before treatment with biologicals in Indian patients with rheumatic diseases. Indian J Rheumatol 2018;13:233–9.
  22. Central TB Division. India TB Report 2019. Revised National Tuberculosis Control Program. Annual Report. New Delhi: Central TB Division, Ministry of Health and Family Welfare Government of India and India TB Report 2020.
  23. TB Risk Factors | Basic TB Facts | TB | CDC. Available at URL: Accessed on July 20, 2020.
  24. Laghari M, Sulaiman SAS, Khan AH, Talpur BA, Bhatti Z, Memon N. Contact screening and risk factors for TB among the household contact of children with active TB: a way to find source case and new TB cases. BMC Public Health 2019;19:1274–83.
  25. Pradipta IS, Forsman LD, Bruchfeld J, Hak E, Alffenaar JW. Risk factors of multidrug-resistant tuberculosis: a global systematic review and meta-analysis. J Infect 2018;77:469–78.
  26. Lönnroth K, Jaramillo E, Williams BG, Dye C, Raviglione M. Drivers of tuberculosis epidemics: the role of risk factors and social determinants. Soc Sci Med 2009;68:2240–6.
  27. Lin S, Melendez-Torres GJ. Systematic review of risk factors for nonadherence to TB treatment in immigrant populations. Trans R Soc Trop Med Hyg 2016;110:268–80.
  28. National AIDS Control Organization and ICMR-National Institute of Medical Statistics (2018). HIV Estimations 2017: Technical Report. New Delhi: NACO, Ministry of Health and Family Welfare, Government of India 2018. Available at URL Accessed on July 24, 2020.
  29. Dravid A, Natarajan K, Medisetty M, Gawali R, Mahajan U, Kulkarni M, et al. Incidence of tuberculosis among HIV infected individuals on long term antiretroviral therapy in private healthcare sector in Pune, Western India. BMC Infect Dis 2019;19;714.
  30. Mahyoub EM, Garg S, Singh MM, Agarwal P, Gupta VK, Gupta N. HIV and TB co-infection in Indian context. J Commun Dis 2013;45:25–32.
  31. Agarwal U, Kumar A, Behera D. Profile of HIV associated tuberculosis at a tertiary institute in setting of free antiretroviral therapy. J Assoc Physicians India 2009;57:685–90.
  32. Gupte AN, Kadam D, Sangle S, Rewari BB, Salvi S, Chavan A, et al. Incidence of tuberculosis in HIV-infected adults on first- and second-line antiretroviral therapy in India. BMC Infect Dis 2019;19:914.
  33. India State-Level Disease Burden Initiative Diabetes Collaborators. The increasing burden of diabetes and variations among the states of India: the Global Burden of Disease Study 1990–2016. Lancet Global Health 2018;6:e1352–e1362.
  34. International Diabetes Federation. IDF Diabetes Atlas, 9th edition. Brussels, Belgium: 2019. Available at URL: Accessed on February 14, 2020.
  35. Anjana RM, Deepa M, Pradeepa R, Mahanta J, Narain K, Das HK, et al. and ICMR–INDIAB Collaborative Study Group. Prevalence of diabetes and prediabetes in 15 states of India: results from the ICMR-INDIAB populationbased cross-sectional study. Lancet Diabetes Endocrinol 2017;5:e5. Correction to Lancet Diabetes Endocrinol 2017; published online June 7. 8587(17)30174-2.
  36. Restrepo BI. Diabetes and tuberculosis. Microbiol Spectr 2016;4:10.1128/microbiolspec.
  37. Dooley KE, Chaisson RE. Tuberculosis and diabetes mellitus: convergence of two epidemics. Lancet Infect Dis 2009;9:737–46.
  38. Pande T, Huddart S, Xavier W, Kulavalli S, Chen T, Pai M, et al. Prevalence of diabetes mellitus amongst hospitalized tuberculosis patients at an Indian tertiary care center: a descriptive analysis. PLoS One 2018; 13: e0200838.
  39. Mave V, Nimkar S, Prasad H, Kadam D, Meshram S, Lokhande R, et al. Tuberculosis screening among persons with diabetes mellitus in Pune, India. BMC Infect Dis 2017;17:388.
  40. World Health Organization. A WHO/The Union Monograph on TB and Tobacco Control: Joining Efforts to Control Two Related Global Epidemics. Geneva: World Health Organization; 2007.
  41. Mohan P, Lando HA, Panneer S. Assessment of tobacco consumption and control in India. Indian J Clin Med 2018;9:1–8.
  42. GATS. Global Adult Tobacco Survey: fact sheet, India 2016- 17; 2017. Available at URL: Google Scholar. Accessed on July 20, 2020.
  43. National Framework for Joint TB-Tobacco Collaborative Activities. Revised National TB Control Program and National Tobacco Control Program, May 2017. Directorate General of Health Services, Ministry of Health and Family Welfare, Govt of India.
  44. State of Slums in India: A statistical Compendium, 2013. Ministry of Housing and Urban Poverty Alleviation, National Building Organization. Government of India.
  45. Noykhovich E, Mookherji S, Roess A. The risk of tuberculosis among populations living in slum settings: a systematic review and meta-analysis. J Urban Health 2019;96:262–75.
  46. Sarin R, Vohra V, Khalid UK, Sharma PP, Chadha V, Sharada MA. Prevalence of pulmonary tuberculosis among adults in selected slums of Delhi city. Indian J Tuberc 2018;65:130–4.
  47. Capacity of Jails, Inmate Population and Occupancy Rate at the end of 2015. National Crime Records Bureau. Available at URL: Accessed on February 23, 2017.
  48. Prison Statistics India 2018. National Crime Records Bureau. Available at URL: india. Accessed on July 20, 2020.
  49. Time to act to prevent and control tuberculosis among inmates: a statement of The International Union Against Tuberculosis and Lung Disease. Available at URL: pdf?ua=1. Accessed on July 28, 2020.
  50. Guidelines for control of tuberculosis in prisons (TBCTA and ICRC). Available at URL: Accessed on July 28, 2020.
  51. WHO Health in Prisons Project (WHO/EURO). Available at URL: Accessed on July 28, 2020.
  52. WHO collaborating centre on TB in prisons: Medical Department of the Ministry of Justice of Azerbaijan. Available at URL: in-prisons. Accessed on July 28, 2020
  53. United Nations Office on Drugs and Crime (UNODC): health care and HIV/AIDS prevention and care. Available at URL: Accessed on July 28, 2020.
  54. Prasad BM, Thapa B, Chadha SS, Das A, Babu ER, Mohanty S, et al. Status of Tuberculosis services in Indian Prisons. Int J Infect Dis 2017;56:117–21.
  55. Lönnroth K, Jaramillo E, Williams BG, Dye C, Raviglione M. Drivers of tuberculosis epidemics: the role of risk factors and social determinants. Social Sci Med 2009;68:2240–6.
  56. Lönnroth K, Castro K, Chakaya JM, Chauhan LS, Floyd K, Glaziou P, et al. Tuberculosis control and elimination 2010-50: cure, care, and social development. Lancet 2010;375:1814–29.
  57. Sagili KD, Satyanarayana S, Chadha SS. Is knowledge regarding tuberculosis associated with stigmatising and discriminating attitudes of general population towards tuberculosis patients? findings from a community based survey in 30 districts of India. PLoS One 2016;11: e0147274.
  58. Khanday ZA, Akram M. Health status of marginalized groups in India. Int J Applied Sociol 2012;2:60–70.
  59. Rao VG, Gopi PG, Yadav R, Sadacharam K, Bhat J, Subramani R, et al. Tuberculosis infection in Saharia, a primitive tribal community of Central India. Trans Trop Med Hyg 2008;102:898–904.
  60. Rao VG, Gopi PG, Bhat J, Selvakumar N, Yadav R, Tiwari B, et al. Pulmonary tuberculosis: a public health problem amongst Saharia, a primitive tribe of Madhya Pradesh, central India. Int J Infect Dis 2010;14:e713–6.
  61. Rao VG, Bhat J, Yadav R, Muniyandi M, Sharma R, Bhondeley MK. Pulmonary tuberculosis: a health problem amongst Saharia tribe in Madhya Pradesh. Indian J Med Res 2015;141:630–5.
  62. Rao VG, Bhat J, Yadav R Sharma RK, Muniyandi M. Declining tuberculosis prevalence in Saharia, a particularly vulnerable tribal community in Central India: evidences for action. BMC Infect Dis 2019;19:180.
  63. Muniyandi M, Rao VG, Bhat J, Yadav R, Sharma RK, Bhondeley MK. Health literacy on tuberculosis amongst vulnerable segment of population: special reference to Saharia tribe in central India. Indian J Med Res 2015;141:640–7.
  64. Central TB Division. Guidance document: Nutritional care and support for patients with tuberculosis in India. Central TB Division, Ministry of Health and Family welfare, Govt of India, 2017. Available at URL: Document%20-%20Nutritional%20Care%20%26%20 Support%20for%20TB%20patients%20in%20India.pdf. Accessed on August 31, 2020.
  65. Bhargava A. Undernutrition, nutritionally acquired immunodeficiency, and tuberculosis control. Br Med J. 2016;355.
  66. Padmapriyadarsini C, Shobana M, Lakshmi M, Beena T, Swaminathan S. Undernutrition and tuberculosis in India: situation analysis and the way forward. Indian J Med Res 2016;144:11–20.
  67. Scrimshaw NS, SanGiovanni JP. Synergism of nutrition, infection, and immunity: an overview. Am J Clin Nutr 1997;66:464S–77S.
  68. Lonnroth K, Williams BG, Cegielski P, Dye C. A consistent log-linear relationship between tuberculosis incidence and body mass index. Int J Epidemiol 2010;39:149–55.
  69. Bhargava A, Benedetti A, Oxlade O, Menzies D, Pai M. Undernutrition and the incidence of tuberculosis in India: National and subnational estimates of the populationattributable fraction related to undernutrition. Natl Med J India 2014;27:128–33.
  70. Lönnroth K, Castro KG, Chakaya JM, Chauhan LS, Floyd K, Glaziou P, et al. Tuberculosis control and elimination 2010–50: cure, care, and social development. Lancet 2010;375:1814–29.
  71. Cegielski JP, Arab L, Cornoni-Huntley J. Nutritional risk factors for tuberculosis among adults in the United States, 1971-1992. Am J Epidemiol 2012;176:409–22.
  72. 2020 Global Nutrition Report. Action on equity to end malnutrition. UK: Development Initiatives. Available at URL: global-nutrition-report/. Accessed on July 31, 2020.
  73. National Family Health Survey (NFHS-4), India; 2015. 16. Available at URL: Accessed on July 31, 2020.
  74. Nallusamy S, Shyamalapriya, Balaji, Ranjan, Yogendran. Organ donation: current Indian scenario. J Pract Cardiovasc Sci 2018;4:177.9.
  75. Joseph JK, Devu BK. Organ transplantation in India; legal and ethical aspects. Indian J Appl Res 2019;9:36.38.
  76. Subramanian AK, Morris MI: AST infectious diseases: Commun Pract Am J Transplant 2013;13 (Suppl. 4):68.
  77. Guedes G. Tuberculosis and immunosuppression. J Microbiol Exp 2018;6:145.14.
  78. Gras J, De Castro N, Montlahuc C, Champion L, Scemla A, Matignon M, et al. Clinical characteristics, risk factors, and outcome of tuberculosis in kidney transplant recipients: A multicentric case-control study in a lowendemic area. Transpl Infect Dis 2018;20:e12943.
  79. Liu J, Yan J, Wan Q. Ye Q, Huang Y. The risk factors for tuberculosis in liver or kidney transplant recipients. BMC Infect Dis 2014;14: 387.
  80. Sakhuja V, Jha V, Varma PP, Joshi K, Chugh KS. The high incidence of tuberculosis among renal transplant recipients in India. Transplantation. 1996;61:211.5.
  81. Viana L, Cristelli M, Tavares M, Felipe C, Oliveira N, Paula M, et al Tuberculosis in kidney transplant: 10 years of experience (Abstract). Am J Transplant 2013;13(Suppl.5). Available at URL: Accessed on November 25, 2020.
  82. Liu M, Yang C, Liu L, Shi B, Hu W, Ye L, et al. Hematopoietic stem cell transplantation for treatment of patients with leukemia concomitant with active tuberculosis infection. Med Sci Monit 2014;30:2484.8.
  83. Al-Anazi KA, Al-Jasser AM, Alsaleh K. Infections caused by Mycobacterium tuberculosis in recipients of hematopoietic stem cell transplantation. Front Oncol 2014;26:231.
  84. Garcia-Elorriaga G, del Rey-Pineda G. Tuberculosis and hematopoietic stem cell transplant: review of a difficult and often underestimated problem. World J Clin Infect Dis 2013;3:70.78.
  85. Youssef J, Novosad SA, Winthrop KL. Infection risk and safety of corticosteroid use. Rheum Dis Clin North Am. 2016;42:157.76.
  86. Castellana G, Castellana M, Castellana C, Castellana G, Resta E, Carone M, Inhaled corticosteroids and risk of tuberculosis in patients with obstructive lung diseases: a systematic review and meta-analysis of non-randomized studies. Int J Chron Obstruct Pulmon Dis 2019;14:2219.27
  87. Jick SS, Lieberman ES, Rahman MU, Choi HK, et al. Glucocorticoid use, other associated factors, and the risk of tuberculosis. Arthritis Rheum 2006;55:19.26.
  88. Dong YH, Chang CH, Wu FL, Shen LJ, Calverley PMA, Lofdahl CG, et al. Use of inhaled corticosteroids in patients with COPD and the risk of TB and influenza: a systematic review and meta-analysis of randomized controlled trials. a systematic review and meta-analysis of randomized controlled trials. Chest 2014;145:1286.97.
  89. Pinto BM, Gama L, Miranda C, Vargas R, Santos AP, Costa W, et al. Immunosuppressant drugs and tuberculosis: patient's features in a University Hospital. Am J Respir Crit Care Med 2016;193:A5524.
  90. Machuca I, Vidal E, de la Torre-Cisneros J, Rivero- Roman A. Tuberculosis in immunosuppressed patients. Enferm Infecc Microbiol Clin 2018;36:366.74.
  91. Millar JW, Horne NW. Tuberculosis in immunosuppessed patients. Lancet 1979;313:1176.8.
  92. Keane J, Bresnihan B. Tuberculosis reactivation during immunosuppressive therapy in rheumatic diseases: diagnostic and therapeutic strategies. Curr Opin Rheumatol 2008;20:443.9.
  93. Valk PV, Crevel RV, Steenwinkel JJ, Bakker M, Vonkeman H, Hest RV. New guidelines for screening for tuberculosis and latent tuberculosis infection pre-immunosuppressive therapy in the Netherlands: a targeted and stratified approach. Eur Respir J 2019;54:PA557.
  94. Pal D, Behera D, Gupta D, Aggarwal A. Tuberculosis in patients receiving prolonged treatment with oral corticosteroids for respiratory disorders. Indian J Tuberc. 2002;49:83.86.
  95. Agrawal PN, Gupta D, Aggarwal AN, Behera D. Incidence of tuberculosis among patients receiving treatment with oral corticosteroids. J Assoc Physicians India 2000;48:881.4.
  96. Keane J, Gershon S, Wise RP, Mirabile-Levens E, Kasznica J, Schwieterman WD, et al. Tuberculosis associated with infliximab, a tumor necrosis factor-alpha neutralizing agent. N Engl J Med 2001;345:1098.104.
  97. Gardam MA, Keystone EC, Menzies R, Manners S, Skamene E, Long R, et al. Anti-tumour necrosis factor agents and tuberculosis risk: mechanisms of action and clinical management. Lancet Infect Dis 2003;3:148.55.
  98. Arend SM, Breedveld FC, Van Dissel JT. TNF-ƒ¿ blockade and tuberculosis: better look before you leap. Netherland J Med 2003;61:111.9.
  99. Esmail H, Wilkinson RJ. Minimizing tuberculosis risk in patients receiving anti-TNF therapy. Ann Am Thorac Soc 2017;14:621.3.
  100. Sakkat A, Cox GP, Khalidi A, Renzoni EA, Morar N, et al. Infliximab therapy in patients with refractory sarcoidosis: a multicenter retrospective review. Am J Respir Crit Care Med 2020;201:A1555.
  101. Baussano I, Nunn P, Williams B, Pivetta E, Bugiani M, Scano F. Tuberculosis among health care workers. Emerg Infect Dis 2011;17:488.95.
  102. Dimitrova B, Hutchings A, Atun R, Drobniewski F, Marchenko G, Zakharova S, et al. Increased risk of tuberculosis among health care workers in Samara Oblast, Russia: analysis of notification data. Int J Tuberc Lung Dis 2005;9:43.8.
  103. Joshi R, Reingold AL, Menzies D, Pai M. Tuberculosis among health-care workers in low- and middle-income countries: a systematic review. PLoS Med 2006;3:e494.
  104. Christopher DJ, Daley P, Armstrong L, James P, Gupta R, Premkumar B, et al. Tuberculosis infection among young nursing trainees in South India. PLoS One 2010;5(4):e10408.
  105. Woith WM, Volchenkov G, Larson JL. Russian healthcare workers' knowledge of tuberculosis and infection control. Int J Tuberc Lung Dis 2010;14:1489–92.
  106. Verkuijl S, Middelkoop K. Protecting our front-liners: occupational tuberculosis prevention through infection control strategies. Clin Infect Dis 2016;62(Suppl. 3):S231-S7.
  107. Rao KG, Aggarwal AN, Behera D. Tuberculosis among physicians in training. Int J Tuberc Lung Dis 2004; 8:1392–4.
  108. Khayyam KU, Patra S, Sarin R, Behera D. Tuberculosis among health care workers in a tertiary care institute for respiratory diseases in New Delhi. Indian J Tuberc 2010;57:192–8.
  109. Cowie RL. The epidemiology of tuberculosis in gold miners with silicosis. Am J Respir Crit Care Med 1994;150(5 Pt 1):1460.
  110. Hnizdo E, Murray J. Risk of pulmonary tuberculosis relative to silicosis and exposure to silica dust in South African gold miners. Occup Environ Med 1998;55:496–502.
  111. Rees D, Murray J. Silica, silicosis and tuberculosis. Int J Tuberc Lung Dis 2007;11:474–84.
  112. Pneumoconioses [Internet]. Atlanta: National Institute for Occupational Safety and Health; 2016. Available at URL: Accessed on August 12, 2020.
  113. Elimination of silicosis. GOHNET Newsletter. 2007;(13):1–36. Geneva: World Health Organization;
  114. Available at URL: Accessed on August 12, 2020.
  115. Kim YM, Kim M, Kim SK, Park K, Jin SH, Lee US, et al. Mycobacterial infections in coal workers' pneumoconiosis patients in South Korea. Scand J Infect Dis 2009;41:656–662.
  116. Jindal SK. Silicosis in India: past and present. Curr Opin Pulm Med 2013;19:163–8.
  117. Sharma N, Kundu D, Dhaked S, Das A. Silicosis and silicotuberculosis in India. Bull World Health Organ 2016;94:777–8.
  118. Kulkarni GK. Prevention and control of silicosis: a national challenge. Ind J Environ Med 2007;11:95–96.
  119. Silicosis. National Health Portal of India, 2018. Available at URL: Accessed on August 12, 2020.
  120. Gupta A. Silicosis: an uncommonly diagnosed common occupational disease. ICMR Bull 1999;29:1–7.
  121. Viswanathan R, Boparai MS, Jain SK, Dash MS. Pneumoconiosis survey of workers in an ordnance factory in India. Arch Environ Health 1972;25:198–204.
  122. Saiyed HN, Parikh DJ, Ghodasara NB, Sharma YK, Patel GC, Chatterjee SK, et al. Silicosis in slate pencil workers. I An environmental and medical study. Am J Ind Med 1985;8:127–33.
  123. Malik SK, Behera D, Awasthi GK, Singh JP. Pulmonary silicosis in emery polish workers. Indian J Chest Dis Allied Sci 1985;27:116–21.
  124. Kulkarni GK. Prevention and control of silicosis: a national challenge. Indian J Occup Environ Med 2007;11:95–6.
  125. Sharma SK, Ryan H, Khaparde S, Sachdeva KS, Singh AD, Mohan A, et al. Index-TB guidelines: Guidelines on extrapulmonary tuberculosis for India. Indian J Med Res 2017;145:448–63.
  126. Report of the first National Anti-TB Drug Resistance Survey, India. 2014-16. Ministry of Health and Family Welfare, Govt of India, WHO India, USAID and National Health Mission. Available at URL: Accessed on August 12, 2020.
  127. Central TB Division Guidelines on Programatic Management of Drug Resistant Tuberculosis in India, 2017. Revised Tuberculosis Control Program, Ministry of Health and Family Welfare, Govt of India
  128. Central TB Division Guidelines for use of delemanid in the treatment of drug-resistant TBs in India, 2018. Revised Tuberculosis Control Program. New Delhi Central TB Division, Ministry of Health and Family Welfare, Government of India
  129. Sarin R, Singla N, Vohra V, Singla R, Puri MM, Munjal S, et al. Initial experience of bedaquiline implementation under the National TB Programme at NITRD, Delhi, India. Indian J Tuberc 2019;66:209–13.
  130. Sarin R, Vohra V, Singla N, Singla R, Puri MM, Munjal SK, et al. Early efficacy and safety of bedaquiline and delamanid given together in a “Salvage Regimen” for treatment of drug-resistant tuberculosis. Indian J Tuberc. 2019;66:184–8.
  131. Behera D. TB control in India in the COVID era [published online ahead of print, 2020 Aug 28]. Indian J Tuberc 2020;doi:10.1016/j.ijtb.2020.08.019.
  132. Sharma SK, Mohan A, Chauhan LS, Narain JP, Kumar P, Behera D, et al. Contribution of medical colleges to tuberculosis control in India under the Revised National Tuberculosis Control Programme (RNTCP): lessons learnt and challenges ahead. Indian J Med Res. 2013;137:283–94.
  133. Parmar MM, Sachdeva KS, Rade K, Ghedia M, Bansal A, Nagaraja SB, et al. Airborne infection control in India: baseline assessment of health facilities. Indian J Tuberc 2015;62:211–7.
  134. Sachdeva KS, Deshmukh RD, Seguy NS, Nair SA, Rewari BB, Ramchandran R, et al. Tuberculosis infection control measures at health care facilities offering HIV and tuberculosis services in India: a baseline assessment. Indian J Tuberc 2018;65:280–4.
  135. Guidelines on Airborne Infection Control in Healthcare and Other Settings. Directorate General of Health Services Ministry of Health and Family Welfare Nirman Bhawan, New Delhi, 2010.
  136. Centers for Disease Control and Prevention. Treatment regimens for latent TB infection. Available at URL: www. Accessed on August 12, 2020.
  137. World Health Organization. Latent tuberculosis infection Updated and consolidated guidelines for programmatic management. Geneva: World Health Organization; 2018.
  138. Mahasha PW, Ndwandwe DE, Mavundza EJ, Shey M, Wiysonge CS. Systematic review protocol on Bacillus Calmette-Guerin (BCG) revaccination and protection against tuberculosis. BMJ Open 2019;9:e027033.
  139. Indian Council of Medical Research. A phase III, randomized, double-blind, three arm placebo controlled trial to evaluate the efficacy and safety of two vaccines VPM1002 and immuvac(Mw) in preventing tuberculosis (TB) in healthy household contacts of newly diagnosed sputum positive pulmonary TB patients. ICMR TB Consortium (under trial; CTRI/2019/01/017026 [Registered on: 10/01/2019]).
  140. Varma-Basil M, Nair D. Molecular epidemiology of tuberculosis: Opportunities & challenges in disease control. Indian J Med Res 2017;146:11–14.
  141. World Health Organization. Advocacy, Communication and Social Mobilization (ACSM) for Tuberculosis Control. Geneva: World Health Otganization, 2007.
  142. Central TB Division, Ministry of Health and Family Welfare, Govt of India. IEC material 2019. Revised Tuberculosis Control Program.
  143. Dhar R, Singh S, Talwar D, Mohan M, Tripathi SK, Swarnakar R, et al. Bronchiectasis in India: results from the European Multicentre Bronchiectasis Audit and Research Collaboration (EMBARC) and Respiratory Research Network of India Registry. Lancet Global Health 2019;7:e1269–e79.
  144. Singla N, Singla R, Fernandes S, Behera D. Post treatment sequelae of multi-drug resistant tuberculosis patients. Indian J Tuberc 2009;56:206–12.
  145. Gandhi K, Gupta S, Singla R. Risk Factors associated with post-TB sequele. Indian J Tuberc 2016;63:34–38
  146. Ravimohan S, Kornfeld H, Weissman D, Bisson GP. Tuberculosis and lung damage: from epidemiology to pathophysiology. Eur Respir Rev 2018;27:170077.
  147. Singla R, Mallick M, Mrigpuri P, Singla N, Gupta A. Sequelae of MDR-TB at treatment completion. Lung India 2018;35:4–8.
  148. Singh S, Collins BF, Sharma BB, Joshi JM, Talwar D, Katiyar S, et al. Interstitial lung disease in India: results of a Prospective Registry. Am J Respir Crit Care Med 2017;195:801–13.
  149. Agarwal R, Denning DW, Chakrabarti A. Estimation of the burden of chronic and allergic pulmonary aspergillosis in India. PLoS One 2014;9:e114745.
  150. Behera D. Complications of pulmonary tuberculosis. In: Sharma SK, and Mohan Alladi, edditors Tuberculosis; 2nd edition. 2009;pp 519-31 and Text Book of Tuberculosis and Non-Tuberculous Mycobacteria. 3rd edition, 2020.
  151. Behera D. Tuberculosis, COVID-19, and the End Tuberculosis strategy in India. Lung India 2020;37:467–72.
PDF Share
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.